Controlled Substances
Substances regulated under narcotics and psychotropics legislation due to their potential for addiction and abuse, requiring specific licensing, security, and record-keeping for manufacture, distribution, and use.
Foresight tracks Controlled Substances developments and surfaces the alerts most likely to matter before they turn into missed deadlines, recalls, or escalation work.
Not ready for a trial? Take the 3-minute readiness assessment
Current activity
Intensifying
112% above the prior 8-week baseline
3-month trend
Latest alerts below
Last updated
12 May 2026, 18:21
Latest Controlled Substances alerts
The most recent regulatory and guidance signals tracked by Foresight
US FDA Announces Recall of Better Weather Fix Elixir Dietary Supplements for Undeclared Mitragynine and Mitragynine Pseudoindoxyl
In May 2026, the US FDA announced a voluntary recall of Better Weather Fix Elixir dietary supplements after testing found undeclared mitragynine and the more potent mitragynine pseudoindoxyl in approximately 448 boxes of product. This highlights regulatory and liability risks for companies marketing kratom-related or other pharmacologically active ingredients as dietary supplements without transparent labelling and robust ingredient controls.
United StatesCalifornia AB 2249: Appropriations Hearing Set on Cannabis Packaging and Marketing
California’s AB 2249 would tighten cannabis packaging, labelling and marketing rules to prevent products being attractive to children, with the bill now set for an Assembly Appropriations Committee hearing on 14 May 2026. If advanced, cannabis manufacturers and retailers should prepare for stricter state oversight of branding and packaging designs, with new DCC rubrics and binding packaging determinations expected by mid-2027.
United StatesItaly Ministry of Health Updates DPR 309/1990 Tables I and IV With New Psychoactive Substances
An April 2026 decree from Italy’s Ministry of Health adds new synthetic cannabinoids, dissociative drugs and the sedative avizafone to the narcotics schedules under DPR 309/1990, effective from 24 May 2026. This brings emerging psychoactive substances into Italy’s strict controlled-substances regime, tightening requirements for manufacturers, importers, distributors and healthcare providers around licensing, prescribing, storage and record-keeping.
ItalyArgentina Ministry Of Security Resolution MSEG No. 424 Updates RENPRE Administrative Procedures Manual
On 08 May 2026 Argentina’s Ministry of Security published Resolution MSEG No. 424 updating the administrative procedures manual for the National Register of Chemical Precursors (RENPre). This signals adjustments to how obligations for registered precursor operators are administered, so companies handling listed chemical precursors in Argentina should review the updated manual and verify any impact on their registration and compliance processes.
ArgentinaNew Jersey Assembly Introduces Bill A5051 To Revise Hemp Beverage And Medical Cannabis Restrictions
In May 2026 New Jersey introduced Assembly Bill A5051 to extend and refine state rules on hemp-derived intoxicating beverages and medical cannabis licensing, building on the recently enacted S3945 framework. If adopted, it would push key compliance deadlines to November 2026, tighten permitted beverage container formats while adding 90–110% lab-test tolerance, and relax but structure retail display rules, requiring licensees to adjust product formulations, labelling, and store operations.
United StatesIowa Bill HSB753 Proposes New Framework For Hemp And Associated Products
Iowa lawmakers are considering House Study Bill 753, a comprehensive overhaul of the state’s hemp and hemp product framework that cleared its first House committee step in February 2026. If enacted, the bill would formalise hemp as an agricultural commodity, tighten controls on THC levels and synthetic cannabinoids, pre-empt local rules, and create new age limits and penalties for growers, processors, and retailers of hemp-derived products in Iowa.
United StatesMinnesota Senate Finance Committee Reports Omnibus Cannabis Bill S.F. 4401 With New Product Limits And Medical Cannabis Endorsements
In May 2026, the Minnesota Senate Finance Committee advanced omnibus cannabis bill S.F. 4401, tightening product limits and reshaping licensing for cannabis and hemp-derived products while adding new medical cannabis endorsements and requiring analysis of federal funding for a psilocybin therapeutic use programme. If enacted, the package would force manufacturers and retailers to adjust formulations, labeling, and licensing strategies across Minnesota’s cannabis and hemp markets and signal a more structured approach to medical cannabis and psychedelic therapies.
United StatesUK Home Office Publishes Drug Precursor Chemical Category and CN Code Guidance
On 8 May 2026 the UK Home Office published guidance consolidating four categories of controlled drug precursor chemicals and their associated CN customs codes for use in the UK. This clarified mapping of substances to tariff codes strengthens compliance for chemical suppliers and traders by indicating which chemicals are treated as drug precursors in Great Britain and Northern Ireland and where EU-aligned controls still apply.
United KingdomMissouri SB1724 Referred to Judiciary Committee; Would Classify Xylazine as Schedule III Controlled Substance
Missouri’s SB1724 would classify the veterinary sedative xylazine as a Schedule III controlled substance while preserving specified authorised animal-health uses, and it has advanced to the Senate Judiciary and Civil and Criminal Jurisprudence Committee in May 2026. If enacted, manufacturers, distributors, veterinarians, and pharmacies operating in Missouri would face tighter controls and monitoring around xylazine, so they should begin assessing supply chains, prescribing practices, and diversion-prevention measures in anticipation of possible passage.
United StatesColorado HB1325 Would Create Ibogaine Research Pilot Program and Rulemaking Powers
Colorado’s HB1325 has cleared second reading in the House and would create an ibogaine research pilot program, expand Colorado’s natural medicine framework to cover semi-synthetic ibogaine, and authorise rules for ibogaine administration and manufacturing. If enacted, ibogaine developers and treatment providers in Colorado should expect new state licensing conditions, manufacturing standards, and benefit-sharing obligations tied to ibogaine sourcing and use over the coming years.
United StatesNew Hampshire Senate Adopts Ought-To-Pass Motion On HB 1630 Nitrous Oxide Sale Ban
In May 2026 the New Hampshire Senate advanced HB 1630, a bill to ban most retail nitrous oxide devices for recreational use and tighten inhalant controls on liquor-licensed premises, with a planned effective date of January 2027 if enacted. If the bill becomes law, retailers and hospitality operators holding liquor licences in New Hampshire will need to remove affected products, revise compliance programmes, and monitor further rulemaking and enforcement by the liquor commission.
United StatesIndiana Department of Health Publishes Q1 2026 Toxicology Trends on Emerging Synthetic Opioids and Adulterants
Indiana’s Department of Health has released Q1 2026 toxicology findings showing a shifting mix of drugs in suspected overdose deaths, with notable signals around highly potent synthetic opioids (including carfentanil and emerging orphine analogues), veterinary sedatives (xylazine and medetomidine) and designer benzodiazepines and adulterants. For compliance and risk teams this is an early-warning signal that these molecules and their analogues may face tighter scheduling, testing and control requirements over time, warranting closer monitoring of DEA and state-level actions that could affect substance management, drug-supply oversight and related workplace policies.
United StatesNetherlands NVWA Warns About Dangerous Substances in Libido-Enhancing Supplements
In April 2026 the Dutch authority NVWA warned that five libido-enhancing supplements marketed as natural contain undeclared prescription drugs (sildenafil, tadalafil and morphardenafil) and has added them to its national Blocklist. This reinforces regulatory scrutiny of hidden pharmaceutical ingredients in dietary supplements, increasing enforcement and liability risk for manufacturers, importers and online retailers selling sexual enhancement products into the Dutch market.
NetherlandsUS Senate Bill S. 4446 (PRESS Act) Proposes New Offence for Illicit Pill-Press Equipment
The US Senate has introduced the Preventing Rogue Equipment for Synthetic Substances (PRESS) Act, which would create a new federal offence and higher penalties for manufacturing or supplying pill presses and related equipment intended to produce controlled substances for unlawful import into the United States. If adopted, it would expand extraterritorial enforcement under the Controlled Substances Import and Export Act, signaling tighter scrutiny of foreign equipment suppliers and chemical manufacturers connected to counterfeit synthetic drug production.
United StatesNebraska Enacts LB795 Adding Bromazolam to Uniform Controlled Substances Act and Tightening Fentanyl Penalties
In March 2026 Nebraska enacted LB795, adding bromazolam to the state's Uniform Controlled Substances Act and increasing penalties for certain fentanyl offenses. This raises compliance and enforcement risk around bromazolam and fentanyl in Nebraska, requiring controlled-substance handlers to update scheduling, prescribing, inventory, and diversion-control practices.
United StatesCanada Adds R 29676 to Precursor Control Regulations Schedule (SOR/2026-73)
Canada has adopted SOR/2026-73 to add R 29676 and its salts to the Schedule of the Precursor Control Regulations, with the order taking effect on 5 June 2026. This brings the substance under Canada’s controlled precursor regime with no de minimis threshold, so manufacturers, importers, distributors and laboratories must review portfolios and compliance systems for potential exposure.
CanadaCanada Amends Food and Drug Regulations and Controlled Substances Regulations for Spirobrorphine and Spirochlorphine (SOR/2026-72)
Canada has adopted Order SOR/2026-72 to bring the substances spirobrorphine and spirochlorphine and their salts under time-limited control through amendments to the Food and Drug Regulations and the Controlled Substances Regulations effective from June and October 2026. Companies manufacturing, importing or handling these substances in Canada will need to prepare for new licensing, record-keeping and other compliance obligations under these frameworks across the continuous control period from June 2026 to June 2027.
CanadaCanada Temporarily Adds R 29676, Spirochlorphine and Spirobrorphine to Schedule V of the Controlled Drugs and Substances Act (SOR/2026-71)
Canada has temporarily added synthetic opioids spirochlorphine and spirobrorphine and the precursor R 29676 to Schedule V of the Controlled Drugs and Substances Act from 5 June 2026 to 4 June 2027 via Order SOR/2026-71. This one-year control brings these substances under Health Canada’s controlled-substance and Class A precursor licensing regimes, tightening authorisation and permitting requirements for laboratories, reference standard suppliers and other handlers while signalling potential longer-term scheduling.
CanadaUK Updates Export Drugs and Medicines Certificate Schedule Templates
The UK government has updated its export guidance for drugs and medicines to consolidate veterinary export certificate schedules into a single template document as of early May 2026. This is a minor but operationally relevant documentation change, and exporters of veterinary medicines should switch to the new combined schedules when preparing Defra and VMD export certificate applications to avoid using outdated forms.
United KingdomNetherlands: Gelderland District Court Convicts MDMA Lab Operator for Environmental Offences
In April 2026 the Gelderland District Court sentenced an individual to 52 months’ imprisonment and ordered €38,526 in environmental remediation costs for MDMA production waste that contaminated soil and the Lower Rhine. This case highlights strong Dutch enforcement against hazardous drug-related waste under general environmental law, signalling significant personal liability risk for serious waste and water-pollution offences.
NetherlandsRelated topics
Not a newsletter. Not a feed.
Structured intelligence mapped to your business.
These are just a few of the most recent Controlled Substances alerts. Foresight tracks every jurisdiction, every day — and surfaces only what affects your portfolio, with full citations and evidence.
Start free trialFrequently asked questions
Everything you need to know about Foresight's regulatory intelligence platform
Still have questions? Get in touch with our team
Join 3,500+ professionals staying ahead
Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.
Free forever. Unsubscribe anytime.
Read by professionals at
